Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of ONO-7429 in Participants With Unresectable Advanced or Recurrent Solid Tumors
Sponsor: Ono Pharmaceutical Co., Ltd.
Summary
This study is to evaluate the tolerability and safety of ONO-7429 in participants with unresectable advanced or recurrent solid tumors.
Official title: A Phase 1, Open-label, Dose Escalation Study to Investigate the Safety and Tolerability of ONO-7429 in Participants With Unresectable Advanced or Recurrent Solid Tumors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2026-06-19
Completion Date
2030-03
Last Updated
2026-08-26
Healthy Volunteers
No
Conditions
Interventions
ONO-7429
Specified dose on specified days
Locations (10)
National Cancer Center Hospital East
Kashiwa, Chiba, Japan
Gunma University Hospital
Maebashi, Gunma, Japan
Niigata Cancer Center Hospital
Niigata, Niigata, Japan
Kansai Medical University Hospital
Hirakata, Osaka, Japan
Osaka International Cancer Institute
Osaka, Osaka, Japan
Kindai University Hospital
Sakai, Osaka, Japan
Saitama Medical University International Medical Center
Hidaka, Saitama, Japan
Shizuoka Cancer Center
Sunto-gun, Shizuoka, Japan
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
The Cancer Institute Hospital of JFCR
Koto-ku, Tokyo, Japan